MedTrace Logo

Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency

NCT01507454 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1613

Last updated 2017-02-08

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this study is to investigate the self-reported impact of Vagifem® (estradiol) treatment on urogenital discomfort in women with atrophic vaginitis due to oestrogen deficiency.

Conditions

Interventions

DRUG

estradiol, 25 mcg

Vaginal tablets for 6-12 weeks according to product labelling

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01507454 on ClinicalTrials.gov